From the Research
The PRIME Care trial by Oslin et al. (2022) is not directly related to the provided evidence, which focuses on hypertension treatment with calcium channel blockers and ACE inhibitors. However, considering the provided evidence, the most effective approach to treating hypertension involves combining drugs from different classes to minimize adverse effects and maximize the antihypertensive effect.
- The combination of an ACE inhibitor and a calcium channel blocker is considered an optimal combination for the treatment of hypertension, as shown in the ASCOT-BPLA study 1.
- This combination has been shown to be effective in reducing blood pressure and preventing cardiovascular complications, with a fixed combination of perindopril and amlodipine being a particularly effective option 1.
- The use of calcium channel blockers, such as lercanidipine, has also been shown to be effective in treating hypertension, with a lower incidence of peripheral edema compared to other calcium channel blockers like amlodipine 2.
- Combination therapy with ACE inhibitors and calcium channel blockers has been shown to have a complementary profile, both in their hemodynamic and local vascular action, making it a useful approach for patients with hypertension 3. Therefore, based on the provided evidence, the combination of an ACE inhibitor and a calcium channel blocker is recommended as a first-line treatment for hypertension, due to its effectiveness in reducing blood pressure and preventing cardiovascular complications, and its potential to improve patient outcomes in terms of morbidity, mortality, and quality of life.